Rasagiline is used for the treatment of Parkinson’s disease and is administered orally at a dosage of 1mg, once a day, the dosage is not affected by food intake and should be used under the supervision of a physician. Rasagiline is a selective B-type monoamine oxidase irreversible inhibitor, suitable for the treatment of primary Parkinson’s disease, can be combined with levodopa for the treatment of Parkinson’s disease agent end fluctuations. Rasagiline is an oral drug, the use of 1 mg once a day, with or without food, independent of eating, but can be fixed at the same time of day, to prevent forgetting. Rasagiline is contraindicated in people with a history of hypersensitivity to the components of this drug, in patients with severe hepatic impairment, and should not be combined with other monoamine oxidase inhibitors or pethidine, which must be separated by at least 14 days. Rasagiline may cause adverse reactions such as decreased appetite, anisocoria, abnormal dreams, upright hypotension, abdominal pain and constipation. Resagiline should be used strictly under medical supervision and if discomfort occurs, consult a physician immediately.